Report Information

More information from: https://www.marketresearchfuture.com/reports/real-time-pcr-qpcr-market-10672

Real-Time PCR (qPCR) Market Research Report - Forecast till 2030

Report / Search Code: MRFR/HC/9188-HCR **Publish Date:** May, 2023

Request Sample

Price	1-user PDF : $ 4950.0	Enterprise PDF : $ 7250.0

Description:

Global Real-Time PCR (qPCR) Market Overview

The Real-Time PCR (qPCR) Market Size was valued at USD 5.5 billion in 2022. The Real-Time PCR (qPCR) market industry is projected to grow from USD 5.99 Billion in 2023 to USD 10.00 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.12% during the forecast period (2023 - 2030).Real-time PCR is in greater demand because of the COVID-19 pandemic, the rising incidence of the illnesses it detects, and advances in qPCR technology. These are just a few market drivers driving the Real-Time PCR (qPCR) market.

Real-Time PCR (qPCR) Market

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Real-Time PCR (qPCR) Market Trends

- **Rising Incidence of Genetic Disorders & Life-Threatening Infectious Diseases will boost the market growth**

The major factors propelling the growth of the Digital PCR (dPCR) and Real-time PCR (qPCR) Market during the forecast period include the increasing prevalence of genetic disorders, target infectious disease, increasing use of biomarker profiling for disease diagnostics, and the completion of the Human Genome Project successfully. The need for Digital PCR (dPCR) is anticipated to rise in the next years due to rising technological breakthroughs in PCR technologies, as well as rising investments, funding, and grants. Growth in the prevalence of target diseases around the world coupled with the proven effectiveness of clinical diagnostic tests like Digital PCR (dPCR) and Real-time PCR (qPCR) Market analysis in the diagnosis and valuation of disease-causing microbes will drive the use of these tests, which are anticipated to help the Market grow throughout the forecast period. During the forecast period, the Real-Time PCR (qPCR) market is expected to grow at a faster rate due to increasing market penetration in emerging nations and a shift in consumer perception from plant-delivered drugs to genome-based drugs. Additionally, the shift from plant-based to genome-based drug discovery would provide room for the Market for digital PCR (dPCR) and Real-time PCR (qPCR) to expand in the future. Additionally, it is anticipated that during the projection period, the expansion of the Digital PCR (dPCR) and Real-time PCR (qPCR) Market will be constrained by PCR's technological constraints and the rising cost of PCR instruments. Thus, this factor is driving the market CAGR.

For instance, the SARS-CoV-2 ddPCR Kit from Bio-Rad received Emergency Use Authorization (EUA) from the U.S. FDA in September 2020 to be used in the detection of SARS-CoV-2 infection. To lessen the effects of the COVID-19 epidemic, regulatory bodies have also stated their strong support for the approval of these tests. Further, the significance of qPCR and dPCR technologies in genomics research is emphasized by governments and federal bodies throughout the globe. Additionally, during the past ten years, the qPCR and dPCR sectors have experienced financial initiatives from governmental and business entities to support genomic research. Thus, this aspect will accelerate Real-Time PCR (qPCR) market revenue globally.

Real-Time PCR (qPCR) Market Segment Insights

Real-Time PCR (qPCR) Product Insights

The Real-Time PCR (qPCR) market segmentation, based on Product, includes Reagents & Consumables, Instruments, Software & Services. The arabica segment held the majority share in 2022 in the Real-Time PCR (qPCR) market data. The Market for qPCR reagents and consumables is anticipated to grow as a result of factors such as the expanding applications of qPCR (due to its technological advantages over traditional PCR, such as real-time analysis and reduced analysis

time), increasing private-public funding for life science research, and the rise in probe-based multiplex genetic analysis procedures (which call for the analysis of low-volume gene samples).

Real-Time PCR (qPCR) Application Insights

Based on application, the Real-Time PCR (qPCR) market segmentation includes Clinical, Research, and Forensics. The Clinical segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Spectroscopy and liquid chromatography, two cutting-edge molecular diagnostic methods, are being linked with qPCR procedures to provide genomic lab staff the capacity to quickly and accurately identify pathogens. In order to identify antibiotic resistance and gene mutation in the target microorganisms, qPCR has an advantage over other conventional diagnostic methods including immunological testing, biochemical tests, and serological examination of the sample.

Figure 1: Real-Time PCR (qPCR) Market, by Application, 2022 & 2030 (USD Billion)
Real-Time PCR (qPCR) Market, by Application, 2022 & 2030

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Real-Time PCR (qPCR) End-user Insights

The Real-Time PCR (qPCR) market data, based on End-user, & includes Hospitals' Diagnostic Centers, Research Laboratories & Academic Institutes, Pharmaceutical & Biotechnology Companies, Clinical Research Organizations, and Forensic Laboratories. The Hospitals Diagnostic Centers segment dominated the Real-Time PCR (qPCR) market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This can be attributed to the rising demand for early and effective disease diagnosis, and treatment, the rise in the number of dPCR Product launches for diagnostic uses, the advantages of dPCR in disease diagnosis (as compared to other PCR technologies), and the rising level of public awareness of these advantages.

Real-Time PCR (qPCR) Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Real-Time PCR (qPCR) market accounted for USD 2.519 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Because of the region's high illness prevalence, favorable rules, and several government-sponsored programs to expand the healthcare infrastructure. Additionally, the substantial presence of well-known manufacturers in the area and the rising need for quick diagnostic tests would be key drivers of the North American Real-Time PCR (qPCR) market throughout the projected period.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: REAL-TIME PCR (QPCR) MARKET SHARE BY REGION 2022 (%)
REAL-TIME PCR (QPCR) MARKET SHARE BY REGION 2022

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The Asia-Pacific Real-Time PCR (qPCR) Market is anticipated to develop at the fastest CAGR from 2023 to 2030. Due to major advancements in PCR technology made by China and Japan, as well as the growth of healthcare, R&D, and clinical research frameworks by growing nations like India and Australia, the Asia Pacific region is the most profitable Real-Time PCR (qPCR) market. Throughout the anticipated time frame, the Market will have profitable growth prospects. Further, the China Real-Time PCR (qPCR) Market held the largest market share, and the India Real-Time PCR (qPCR) Market was the fastest growing Market in the region.

Europe's Real-Time PCR (qPCR) market accounts for the third-largest market share Real-Time PCR (qPCR) techniques supported by the government and rising demand for Real-Time PCR testing to combat infectious illnesses like COVID-19 are driving the real-time PCR market in Europe. Additionally, the frequency of viral and genetic illnesses, the need for quick diagnoses, and quick technology improvements are all contributing to the real-time PCR (qPCR) Market's expansion. Moreover, U.K. Real-Time PCR (qPCR) Market held the largest market share, and the Germany Real-Time PCR (qPCR) Market was the fastest-growing Market in the region.

Real-Time PCR (qPCR) Key Market Players & Competitive Insights

Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for Real-Time PCR (qPCR). With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming increasingly competitive, Real-Time PCR (qPCR) industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business methods used by producers in the Real-Time PCR (qPCR) industry to benefit customers and increase the market sector. The Real-Time PCR (qPCR) industry has recently given medicine some of the most important advantages. The Real-Time PCR (qPCR) Market major players such as ABL SA Group

(Luxembourg), Agilent Technologies Inc. (U.S.), Analytik Jena AG (Germany), B.D. (U.S.), Bio-Rad LaboratoriesInc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Fluidigm Corporation (U.S.), Lumex Instruments (U.S.), Primerdesign Ltd (U.K.), QIAGEN (Germany), Takara Bio Inc. (Japan), Thermo Fisher Scientific (U.S.), TOYOBO Inc. (Japan), Vela Diagnostics (Singapore) Company.

The California-based life science startup Azure Biosystems is committed to advancing knowledge in uncharted territories. The Azure Cielo Real-time PCR device was introduced by Azure Biosystems (U.S.) in June 2020. This 96-well qPCR machine offers a high level of performance, a small footprint, and an easy workflow. The genomics workflow has been given priority in the sensitivity and reproducibility of the Azure Biosystem.

American medical device and healthcare corporation Abbott Laboratories is headquartered in Abbott Park, Illinois. The m2000 RealTime SARS-CoV-2 EUA test, which runs its operations on the m2000 RealTime System situated in hospitals and reference laboratories worldwide, was introduced by the Abbott (U.S.) corporation in March 2020. Every month, the company hopes to produce 5 million tests.

Key Companies in the Real-Time PCR (qPCR) market include

- ABL SA Group (Luxembourg)
- Agilent Technologies Inc. (U.S.)
- Analytik Jena AG (Germany)
- B.D. (U.S.)
- Bio-Rad LaboratoriesInc. (US
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fluidigm Corporation (U.S.)
- Lumex Instruments (U.S.)
- Primerdesign Ltd (UK)
- QIAGEN (Germany)
- Takara Bio Inc. (Japan)
- Thermo Fisher Scientific (U.S.)
- TOYOBO Inc. (Japan)

Real-Time PCR (qPCR) Industry Developments

February 2022: The COVID-19 PCR tests were expanded by F. Hoffmann-La Roche Ltd. in nations that accepted the C.E. market. It is projected that company expansion will boost its market share.

May 2020: The SARS-CoV-2 multiplex real-time PCR test was given emergency use permission (EUA) by the US FDA to Thermo Fisher Scientific, Inc.

September 2020: Roche Diagnostics gave the cobas BKV test US FDA 510k approval.

May 2020: Abbott Laboratories was approved by the US FDA for a SARS-CoV-2 ass.

Real-Time PCR (qPCR) Market Segmentation

• ABL SA Group (Luxembourg)
• Agilent Technologies Inc. (U.S.)
• Analytik Jena AG (Germany)
• B.D. (U.S.)
• Bio-Rad LaboratoriesInc. (US
• F. Hoffmann-La Roche Ltd (Switzerland)
• Fluidigm Corporation (U.S.)
• Lumex Instruments (U.S.)
• Primerdesign Ltd (UK)
• QIAGEN (Germany)
• Takara Bio Inc. (Japan)
• Thermo Fisher Scientific (U.S.)
• TOYOBO Inc. (Japan)

Real-Time PCR (qPCR) Product Outlook (USD billion, 2018-2030)

- Reagents & Consumables
- Instruments

- Software & Services

Real-Time PCR (qPCR) Application Outlook (USD billion, 2018-2030)

- Clinical
- Research
- Forensics

Real-Time PCR (qPCR) End-User Outlook (USD billion, 2018-2030)

- Hospitals &Diagnostic Centers
- Research Laboratories & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Clinical Research Organizations
- Forensic Laboratories

Real-Time PCR (qPCR) Regional Outlook (USD Billion, 2018-2030)

- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain

- Rest of Europe

- Asia-Pacific
  - China
  - Japan
  - India
  - Australia
  - South Korea
  - Australia
  - Rest of Asia-Pacific

- Rest of the World
  - Middle East
  - Africa
  - Latin America

Table of Content:

Contents
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Regional Impact
5.3.4. Opportunity and Threat Analysis
6. GLOBAL REAL-TIME PCR (QPCR) MARKET, BY PRODUCT
6.1. Overview
6.2. Reagents & Consumables
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
6.3. Instruments
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
6.4. Software & Services
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
7. GLOBAL REAL-TIME PCR (QPCR) MARKET, BY APPLICATION
7.1. Overview
7.2. Clinical
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
7.3. Research
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
7.4. Forensics
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
7.5. Others
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
8. GLOBAL REAL-TIME PCR (QPCR) MARKET, BY END USER
8.1. Overview
8.2. Hospitals and Diagnostic Centers
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
8.3. Research Laboratories and Academic Institutes
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
8.4. Pharmaceutical and Biotechnology Companies
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
8.5. Others
Market Estimates & Forecast, by Region, 2018–2027
Market Estimates & Forecast, by Country, 2018–2027
9. GLOBAL REAL-TIME PCR (QPCR) MARKET, BY REGION
9.1. Overview
9.2. North America
9.2.1. US
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. Italy
9.3.4. Spain
9.3.5. UK
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Rest of the World
9.5.1. Middle East
9.5.2. Africa
9.5.3. Latin America
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Real-Time PCR (qPCR) Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Real-Time PCR (qPCR) Market
10.7. Key Developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger &Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income,2020
10.8.2. Major Players R&D Expenditure,2020
11. COMPANY PROFILES
11.1. ABL SA Group
11.1.1. Company Overview
11.1.2. Products Offered
11.1.3. Financial Overview

11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Agilent Technologies Inc
11.2.1. Company Overview
11.2.2. Products Offered
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Analytik Jena AG
11.3.1. Company Overview
11.3.2. Products Offered
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. BD
11.4.1. Company Overview
11.4.2. Products Offered
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Bio-Rad Laboratories
11.5.1. Company Overview
11.5.2. Products Offered
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. F-Hoffman-La Roche Ltd.
11.6.1. Company Overview
11.6.2. Products Offered
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Fluidigm Corporation
11.7.1. Company Overview
11.7.2. Products Offered
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Lumex Instruments
11.8.1. Company Overview
11.8.2. Products Offered
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Primerdesign Ltd.
11.9.1. Company Overview
11.9.2. Products Offered
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Qiagen
11.10.1. Company Overview
11.10.2. Products Offered
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. ThermoFisher Scientific
11.11.1. Company Overview
11.11.2. Products Offered
11.11.3. Financial Overview
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Takara Bio Inc.
11.12.1. Company Overview
11.12.2. Products Offered
11.12.3. Financial Overview
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Toyobo Inc.
11.13.1. Company Overview
11.13.2. Products Offered
11.13.3. Financial Overview
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. Vela Diagnostics
11.14.1. Company Overview
11.14.2. Products Offered
11.14.3. Financial Overview
11.14.4. Key Developments
11.14.5. SWOT Analysis

11.14.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL REAL-TIME PCR (QPCR) MARKET SYNOPSIS, 2018–2027
TABLE 2 GLOBAL REAL-TIME PCR (QPCR)MARKET ESTIMATES &FORECAST, 2018–2027 (USD MILLION)
TABLE 3 GLOBAL REAL-TIME PCR (QPCR) MARKET, BYPRODUCT, 2018–2027 (USD MILLION)
TABLE 4 GLOBAL REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 5 NORTH AMERICA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 6 NORTH AMERICA REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 7 US: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 8 US REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 9 CANADA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 10 CANADA REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 11 EUROPE: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 12 EUROPE: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 13 GERMANY: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 14 GERMANY: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 15 UK: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 16 UK: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 17 FRANCE: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 18 FRANCE: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 19 ITALY: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 20 ITALY: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 21 SPAIN: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 22 SPAIN: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 23 REST OF EUROPE: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 24 REST OF EUROPE: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 25 ASIA-PACIFIC: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION,2018–2027 (USD MILLION)
TABLE 27 INDIA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 28 INDIA: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 29 CHINA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 30 CHINA: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 31 JAPAN: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 32 JAPAN: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 33 AUSTRALIA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 34 AUSTRALIA: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 35 SOUTH KOREA: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 36 SOUTH KOREA: REAL-TIME PCR (QPCR) MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 37 REST OF ASIA-PACIFIC: REAL-TIME PCR (QPCR)MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 38 REST OF ASIA-PACIFIC: REAL-TIME PCR (QPCR)MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 39 REST OF THE WORLD: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 40 REST OF THE WORLD: REAL-TIME PCR (QPCR)MARKET, APPLICATION, 2018–2027 (USD MILLION)
TABLE 41 MIDDLE EAST: REAL-TIME PCR (QPCR) MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 42 MIDDLE EAST: REAL-TIME PCR (QPCR)MARKET, APPLICATION, 2018–2027 (USD MILLION)
TABLE 43 AFRICA: REAL-TIME PCR (QPCR)MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 44 AFRICA: REAL-TIME PCR (QPCR)MARKET, APPLICATION,2018–2027 (USD MILLION)
TABLE 45 LATIN AMERICA: REAL-TIME PCR (QPCR)MARKET, BY PRODUCT, 2018–2027 (USD MILLION)
TABLE 46 LATIN AMERICA: REAL-TIME PCR (QPCR)MARKET, APPLICATION, 2018–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL REAL-TIME PCR (QPCR) MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL REAL-TIME PCR (QPCR) MARKET
FIGURE 4 GLOBAL REAL-TIME PCR (QPCR) MARKET SHARE, BY PRODUCT, 2020(%)
FIGURE 5 GLOBAL REAL-TIME PCR (QPCR)MARKET SHARE, BY APPLICATION, 2020(%)
FIGURE 6 GLOBAL REAL-TIME PCR (QPCR) MARKET SHARE, BY REGION, 2020(%)
FIGURE 7 NORTH AMERICA: REAL-TIME PCR (QPCR)MARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 EUROPE: REAL-TIME PCR (QPCR) MARKET SHARE, BY REGION, 2020(%)
FIGURE 9 ASIA-PACIFIC: REAL-TIME PCR (QPCR) MARKET SHARE, BY REGION, 2020(%)
FIGURE 10 REST OF THE WORLD: REAL-TIME PCR (QPCR) MARKET SHARE, BY REGION, 2020(%)
FIGURE 11 GLOBAL REAL-TIME PCR (QPCR) MARKET: COMPANY SHARE ANALYSIS, 2020(%)
FIGURE 12 ABL SA GROUP: KEY FINANCIALS
FIGURE 13 ABL SA GROUP: SWOT ANALYSIS
FIGURE 14 AGILENT TECHNOLOGIES, INC: KEY FINANCIALS
FIGURE 15 AGILENT TECHNOLOGIES, INC:SWOT ANALYSIS
FIGURE 16 ANALYTIK JENA AG: KEY FINANCIALS
FIGURE 17 ANALYTIK JENA AG: SWOT ANALYSIS
FIGURE 18 BD: KEY FINANCIALS
FIGURE 19 BD: SWOT ANALYSIS
FIGURE 20 BIO-RAD LABORATORIES, INC.: KEY FINANCIALS
FIGURE 21 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS
FIGURE 22 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS
FIGURE 23 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
FIGURE 24 FLUIDIGM CORPORATION: KEY FINANCIALS
FIGURE 25 FLUIDIGM CORPORATIONSWOT ANALYSIS
FIGURE 26 LUMEX INSTRUMENTS: KEY FINANCIALS
FIGURE 27 LUMEX INSTRUMENTS: SWOT ANALYSIS
FIGURE 28 PRIMERDESIGN LTD: KEY FINANCIALS
FIGURE 29 PRIMERDESIGN LTD: SWOT ANALYSIS
FIGURE 30 QIAGEN: KEY FINANCIALS
FIGURE 31 QIAGEN: SWOT ANALYSIS
FIGURE 32 TAKARA BIO INC: KEY FINANCIALS
FIGURE 33 TAKARA BIO INC: SWOT ANALYSIS
FIGURE 34 THERMO FISHER SCIENTIFIC: KEY FINANCIALS

FIGURE 35 THERMO FISHER SCIENTIFIC: SWOT ANALYSIS
FIGURE 36 TOYOBO INC: KEY FINANCIALS
FIGURE 37 TOYOBO INC: SWOT ANALYSIS
FIGURE 38 VELA DIAGNOSTICS: KEY FINANCIALS
FIGURE 39 VELA DIAGNOSTICS: SWOT ANALYSIS